ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat

Diabetes

Volumn 51, Issue 11, 2002, Pages 3283-3289

  Wilkinson Berka, Jennifer L ^a   Kelly, Darren J ^b   Koerner, Suzanne M ^a   Jaworski, Kassie ^a   Davis, Belinda ^c   Thallas, Vicki ^c   Cooper, Mark E ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINOGUANIDINE; ANGIOTENSIN; N (2 ACETAMIDOETHYL)HYDRAZINECARBOXIMIDAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BLOOD PRESSURE; CELL DEGENERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HYPERTENSION; KIDNEY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY MASS; KIDNEY MEDULLA; KIDNEY TUBULE; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; TREATMENT PLANNING;

EID: 0036829609     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.11.3283     Document Type: Article

References (38)

1. Steffes MW, Bilous RW, Sutherland DE, Mauer SM: Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 41:679-684, 1992
2. Ziyadeh F: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 22:736-744, 1993
3. Gilbert R, Cooper M: The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56:1627-1637, 1999
4. Cooper M: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic neuropathy. Diabetologia 44:1957-1972, 2001
5. Kelly DJ, Wilkinson-Berka JL, Allen TA, Cooper ME, Skinner SL: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat. Kidney Int 54:343-352, 1998
6. Kelly DJ, Skinner SL, Gilbert RE, Cooper ME, Wilkinson-Berka JL: Differential effects of bosentan and valsartan with respect to progressive diabetic renal pathology in the transgenic (mRen-2)27 rat model. Kidney Int 57:1882-1894, 2000
7. Zatz R, Dunn R, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
8. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL: Increased bradykinin and "normal" angiotensin peptide levels in streptozotocin-diabetic Sprague Dawley and transgenic (mRen-2)27 rats. Kidney Int 56:211-221, 1999
9. Wilkinson-Berka J, Gibbs N, Cooper M, Skinner SL, Kelly D: Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 16:1343-1349, 2001
10. Brownlee M: Advanced glycosylation in diabetes and aging. Annu Rev Med 46:223-234, 1995
11. Soulis-Liparota T, Cooper ME, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin induced diabetic rat. Diabetes 40:1328-1334, 1991.
12. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88: 11555-11558, 1991
13. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37:32-35, 1994
14. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 50:627-634, 1996
15. Tilton R, Chang K, Hasan K, Smith S, Petrash J, Misko T, Moore W, Currie M, Corbett J, McDaniel M, et al: Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
16. Corbett J, Tilton R, Chang K, Hasan K, Ido Y, Wang J, Sweetland M, Lancaster JJ, Williamson J, McDaniel M: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
17. Bank N, Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43:1306-1312, 1993
18. Komers R, Allen TJ, Cooper ME: Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 43:1190-1197, 1994
19. Forbes JM, Soulis T, Thallas V, Pangiotopoulos S, Long D, Vasan S, Wagle D, Jerums G, Cooper M: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114, 2001
20. Bunag RD: Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34:279-382, 1973
21. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G: Glomerular filtration rate in the streptozotocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 38:1182-1190, 1990
22. Saito T, Sumithran E, Glasgow EF, Atkins RC: The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 32:691-699, 1987
23. Soulis T, Thallas V, Youssef S, Gilbert R, McWilliam B, Murraymcintosh R, Cooper M: Advanced glycation end products and their receptors colocalise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40:619-628, 1997
24. Yang C, Vlassara H, Peten E, He C, Striker G, Striker L: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci US A 91:9436-9440, 1994
25. Striker L, Striker G: Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 11 (Suppl. 5):62-65, 1996
26. Yamauchi A, Takei A, Makita Z, Nakamoto S, Ohashi N, Kiguchi H, Ishii T, Koike T, Saruta T: Effects of aminoguanidine on serum advanced glycation endproducts, urinary albumin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract 34:127-133, 1997
27. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899, 1997
28. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42:579-588, 1999
29. Soulis T, Sastra S, Thallas V, Mortensen S, Wilken M, Clausen J, Bjerrum O, Petersen H, Lau J, Jerums G, Boel E, Cooper M: A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 42:472-479, 1999
30. Osicka T, Yu Y, Panagiotopoulos S, Clavant S, Kiriazis Z, Pike R, Pratt L, Russo L, Kemp B, Comper W, Jerums G: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49:87-93, 2000
31. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 61:31-39, 2002
32. Oldfield M, Bach LA, Forbes J, Nikolic-Paterson D, Mcrobert A, Thallas V, Atkins R, Osicka T, Jerums G, Cooper M: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108:1853-1863, 2001
33. Kaneto H, Fujii J, Myint T, Miyazawa N, Islam K, Kawasaki Y, Suzuki K, Nakamura M: Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta cells by provoking oxidative stress through the glycation reaction. Biochem J 320:855-863, 1996
34. Min C, Kang E, Yu S, Shinn S, Kiu Y: AGEs induce apoptosis in human umbilical vein endothelial cells. Diabetes Res Clin Pract 46:197-202, 1999
35. Yanagawa N, Capparelli AW, Jo OD, Friedal A, Barrett JD, Eggena P: Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int 39:938-941, 1991
36. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ: In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. J Clin Invest 85:417-423, 1990
37. Cao Z, Cooper ME: Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 21:554-562, 2001
38. Bonnet F, Cao Z, Cooper ME: Apoptosis and angiotensin II: Yet another renal regulatory system? Exp Nephrol 9:295-300, 2001